Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Expression analysis of human FcRn (FCGRT & B2M) on HEK293/FcRn (FCGRT & B2M), GFP Tag Stable Cell Line by FACS.
The expression of GFP characterizing the human FcRn (FCGRT & B2M) was detected by flow cytometry.
Expression analysis of human FcRn (FCGRT & B2M) on HEK293/Human FcRn (FCGRT & B2M) Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human FcRn (FCGRT & B2M) Stable Cell Line or negative control cell using FITC-Labeled Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F) Protein (Cat. No. IG1-HF2H3).
Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F), His Tag (Cat. No. IG1-H52H8) immobilized on CM4 Chip can bind Human FCGRT&B2M Heterodimer Protein, Strep Tag&Tag Free (Cat. No. FCM-H5283) with an affinity constant of 23.8 nM as determined in a SPR assay (Biacore 8K) (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Efgartigimod alfa | ARGX-113; EFG PH20; EFG PH20 SC; PH20 SC; ARGX-113-2308 | Approved | Argenx Se | VYVGART HYTRULO, VYVDURA, VYVGART, 卫伟迦 | United States | Myasthenia Gravis | Argenx BV | 2021-12-17 | Graves Ophthalmopathy; Tachycardia; Pemphigus; Thrombocytopenia; Guillain-Barre Syndrome; Eye Diseases; Nephrotic Syndrome; Muscular Diseases; Pemphigoid, Bullous; Optic Neuritis; Glomerulonephritis, Membranous; Rejection of organ transplantation; Purpura, Thrombocytopenic, Idiopathic; Lupus Nephritis; Scleroderma, Systemic; Sjogren's Syndrome; Stiff-Person Syndrome; Postural Orthostatic Tachycardia Syndrome; Polyneuropathies; Myositis; Nephrosis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis | Details |
| Rozanolixizumab | UCB-7665 | Approved | Ucb Sa | RYSTIGGO | United States | Myasthenia Gravis | Ucb Inc | 2023-06-27 | Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Encephalitis; Fibromyalgia | Details |
| Efgartigimod alfa/Hyaluronidase | Approved | Argenx BV | VYVDURA, VYVGART HYTRULO | United States | Myasthenia Gravis | Argenx BV | 2023-06-20 | Polymyositis; Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myositis; Dermatomyositis; Autoimmune Diseases; Muscular Diseases | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| IMVT-1402 | IMVT-1402; HL-161 ANS | Phase 2 Clinical | HanAll Biopharma Co Ltd | Autoimmune Diseases; Graves Disease | Details |
| STSA-1301 | STSA-1301; STSA1301 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Purpura, Thrombocytopenic, Idiopathic | Details |
This web search service is supported by Google Inc.
A-Z
